Healthcare investor OrbiMed announced its second debt and royalty fund on Monday and continued to expand efforts to add more healthcare institutions as investors.
The $924 million OrbiMed Royalty Opportunities II will invest between $20 million to $150 million per company. OrbiMed’s various investment funds total $14 billion and cover all of healthcare’s various sectors.
They have most recently invested in IPO-bound Invitae, T-cell therapy Adaptimmune, and vitreoretinal surgery company MID Labs.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
A dozen leading medical research and healthcare institutions contributed to the royalty and credit fund – the most ever, Managing Director Tadd Wessel said. He wouldn’t say how much these strategic partners contributed, but added OrbiMed wants to build something beyond a “pure financial relationship.”
Hopefully, these organizations will begin to use OrbiMed as a source of business development, and they can have a further discussions with OrbiMed about finding companies to address problems they’re having, Wessel said.